SGLT2 inhibitors in patients with HFpEF: how old is too old?

References

[1] Anker SD,Filippatos G.Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med2021;385:1451-61

[2] Committee Members. ACC/AHA joint committee members. 2022 AHA/ACC/HFSA guideline for the management of heart failure.J Card Fail2022;28:e1-e167

[3] Upadhya B,Kitzman DW.Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction.J Am Geriatr Soc2017;65:2431-40 PMCID:PMC5726417

[4] Sanders NA,Lewis EF.The frailty syndrome and outcomes in the TOPCAT trial.Eur J Heart Fail2018;20:1570-7

[5] Böhm M,Filippatos G.Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age.J Am Coll Cardiol2022;80:1-18

[6] Butler J,Filippatos G.Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.Eur Heart J2022;43:416-26 PMCID:PMC8825259

[7] Butler J,Jamal Siddiqi T.Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.Circulation2022;145:184-93 PMCID:PMC8763045

[8] Goldfarb M,Afilalo J.Prognostic and Therapeutic Implications of Frailty in Older Adults with Heart Failure.Curr Cardiol Rep2015;17:92

[9] Filippatos G,Farmakis D.Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.Circulation2022;

[10] Packer M.SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action.Diabetes Care2020;43:508-11